Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Multifunctional nanoplatforms nanomedicine-device combination products: a translational maturity framework spanning nanocoated implants, theranostic platforms, wearable nanosensors, drug-eluting devices, intratumoral nanoparticle injections, and inorganic hybrid nanoplatforms.

Created on 23 Sep 2026

Authors

Abhisar Sahu, Saman Fatima

Published in

Nanomedicine (London, England). Pages 1-13. Sep 22, 2026. Epub Sep 22, 2026.

Abstract

Nanomedicine-device combinations are a heterogeneous product class integrating nanoscale materials with implantable, wearable, and interventional medical devices. Although prior reviews have examined individual technological, regulatory, or clinical aspects of these products, an integrated framework for systematic cross-category comparison is lacking. This review addresses that gap by proposing a Translational Maturity Framework (TMF) synthesizing technology readiness levels (TRLs), regulatory pathway complexity, manufacturing scalability, and clinical evidence strength across six categories: (1) nanocoated and nanostructured implants, (2) theranostic nanoplatforms, (3) nanosensor-integrated wearable devices, (4) drug-eluting devices with nanoparticle payloads, (5) nanoparticle-based intratumoral injections, and (6) inorganic and hybrid nanoplatforms. Using the TMF, we show that intratumoral nanoparticle injections (NBTXR3, NanoTherm) have achieved the highest translational maturity, reflecting their simple design and physics-based mechanisms that ease regulatory classification, while multifunctional theranostic and hybrid platforms face the steepest barriers due to structural complexity and dual diagnostic-therapeutic classification challenges. We identify manufacturing scalability and regulatory classification ambiguity as universal bottlenecks across all six categories, propose a regulatory decision tree for combination-pathway selection, and outline priority research directions for accelerating clinical translation. This framework gives developers, regulators, and investors a structured tool for benchmarking progress and allocating resources in this rapidly evolving field.

PMID:
42773066
Bibliographic data and abstract were imported from PubMed on 23 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 13
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement